Sentences with phrase «target lung cancer cells»

While some research has been done on using apoferritin for drug delivery, this is the first time it was used to target lung cancer cells.

Not exact matches

Many scientists believe that targeting a type of cell called a cancer stem cell may be necessary to completely cure lung cancer.

Although some cancers — particularly those that are rife with mutations like lung cancer or melanoma — create more tangible targets on the surface of cells for the immune system to recognize and attack, other malignancies such as prostate and pancreatic cancers have proved more intransigent.

Beyond lung cancer, TiY is able to target TICs in 28 types of human cell lines derived from the central nervous system, melanoma, breast, renal, ovarian, colon, and prostate cancer.

«Although some non-small cell lung cancer patients have increased benefit of targeted therapy or immunotherapy instead of chemotherapy, for some groups of patients with NSNSCLC, chemotherapy has been the standard treatment for more than 30 years,» Gandhi notes.

However, the Moffitt scientists suggest that it may be possible to target the TGF - β - miR183 - DAP12 pathway in patients with lung cancer to activate the immune system and kill cancer cells.

Using both fruit fly and human lung cancer cell lines, researchers targeted two of the most common genetic mutations associated with NSCLC — Ras and PTEN (P13K).

One successful compound, named Exel 647, that targets nonsmall - cell lung cancer in previously untreated patients is now in a phase 2 clinical trial.

A new drug that targets not only common cancer - causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I / II clinical trial.

The Manchester researchers tested a new drug that targets one of these molecules, MCT1, in lung cancer cells and in mouse models.

The treatment is promising enough that research teams around the world are developing similar stem cell therapies that can target and eradicate cancers of the prostate, lung, breast, skin and other tissues.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

In a study appearing in Science Translational Medicine, the researchers report they have effectively and safely employed this stem cell - targeting system in mice to treat metastatic breast cancer that had spread to the lung.

«Antibody - targeted treatment developed for recurrent small - cell lung cancer.»

MicroRNA -140-3p inhibits proliferation, migration and invasion of lung cancer cells by targeting ATP6AP2.

The FDA granted approval to durvalumab (IMFINZI ®, AstraZeneca), a checkpoint immunotherapy that targets the PD - 1 / PD - L1 pathway, for patients with unresectable, stage III non-small cell lung cancer (NSCLC) that hasn't progressed after prior chemo - radiation treatment.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could aLung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could alung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

More information: Maryna Perepelyuk et al, Evaluation of MUC1 - Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA - 29b to Nonsmall Cell Lung Cancer, Molecular Pharmaceutics (2018).

Together with oncologist William Pao, she uncovered differences in the growth dynamics of non-small cell lung cancer cells that are either resistant or susceptible to the targeted drug Tarceva.

Malfunctioning regulation of NF - KB has been linked to various types of cancer, including lung cancer, but due to its many functions in the cell, drugs that directly target NF - KB would likely cause severe side effects.

Cancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develoCancer Institute research highlights include innovative studies to develop individualized approaches for treatment and prevention of lung cancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer; collaboration between medical and materials science researchers to develop treatments for various types of leukemia using nanotechnology to target only cancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor develocancer cells; and development of novel therapeutics to treat metastatic melanoma using an approach that regulates the processes leading to tumor development.

The once - daily drug targets advanced non-small cell lung cancer, the most common type of lung cancer.